Karl-Heinz Sellinger

Title: The Innovations of Karl-Heinz Sellinger

Introduction

Karl-Heinz Sellinger is a notable inventor based in Weilheim, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of erythropoietin (EPO) compositions. With a total of 2 patents, his work has had a substantial impact on medical science.

Latest Patents

Sellinger's latest patents include innovative methods for producing erythropoietin with high specific activity. The first patent focuses on new EPO compositions characterized by a high proportion of N-acetyl-lactosamine units or tetraantennary branches in the carbohydrate structure. This invention also outlines a process for producing such EPO products. The second patent describes a process for producing erythropoietin that is free of foreign animal proteins, except for the proteins of the host cell. In this process, DNA coding for EPO is expressed in a eukaryotic host cell cultured in a medium devoid of natural mammalian proteins. The erythropoietin is then purified using various chromatography techniques, resulting in a preparation with minimal contamination from host cell proteins and DNA.

Career Highlights

Karl-Heinz Sellinger is currently associated with Roche Diagnostics GmbH, a leading company in the field of diagnostics and biotechnology. His work at Roche has allowed him to focus on innovative solutions that enhance the efficacy and safety of medical treatments.

Collaborations

Throughout his career, Sellinger has collaborated with esteemed colleagues such as Josef Burg and Alexander Wrba. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in biotechnology.

Conclusion

Karl-Heinz Sellinger is a prominent figure in the field of biotechnology, with a focus on erythropoietin innovations. His contributions through patents and collaborations continue to influence medical science and improve patient care.